Prelude Therapeutics Inc <PRLD.OQ> expected to post a loss of 44 cents a share - Earnings Preview
Prelude Therapeutics Inc PRLD.OQ PRLD.O is expected to show no change in quarterly revenue when it reports results on August 11 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for Prelude Therapeutics Inc is for a loss of 44 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Prelude Therapeutics Inc is $4.50, about 81% above its last closing price of $0.86
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.47 | -0.47 | -0.42 | Beat | 10.3 |
Dec. 31 2025 | -0.46 | -0.38 | Beat | 18 | |
Sep. 30 2024 | -0.47 | -0.47 | -0.43 | Beat | 8.9 |
Jun. 30 2024 | -0.43 | -0.43 | -0.46 | Missed | -7 |
Mar. 31 2024 | -0.48 | -0.48 | -0.42 | Beat | 13.4 |
Dec. 31 2023 | -0.49 | -0.49 | -0.46 | Beat | 6.1 |
Sep. 30 2023 | -0.58 | -0.58 | -0.45 | Beat | 22.7 |
Jun. 30 2023 | -0.64 | -0.63 | -0.54 | Beat | 14.7 |
This summary was machine generated August 8 at 16:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
